Literature DB >> 7989978

Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.

T Torizuka1, N Tamaki, T Inokuma, Y Magata, Y Yonekura, A Tanaka, Y Yamaoka, K Yamamoto, J Konishi.   

Abstract

METHODS: Thirty-two tumors in 30 patients with hepatocellular carcinoma (HCC) were studied preoperatively using PET with 18F-labeled 2-fluoro-2-deoxy-D-glucose (FDG) to evaluate the metabolic activity of the lesions after interventional therapy. All patients had received transcatheter arterial chemoembolization therapy using iodized oil (Lipiodol, Laboratoire Guerbet, Alnaysous-Bois, France) before the PET study. The tumors were 2 to 18 cm in diameter. FDG uptake at 48 to 60 min after tracer injection was used to determine the standardized uptake value (SUV). The SUVs of the tumor and nontumor regions of the liver were calculated to obtain the tumor-to-nontumor ratio (SUV ratio). The PET results were compared with the findings of CT and histologic examination.
RESULTS: The tumors were divided into three types, consisting of those with increased FDG uptake (SUV ratio of 1.07-2.66, Type A, n = 19), similar FDG uptake to the surrounding nontumor region (SUV ratio of 0.77-1.04, Type B, n = 7) and decreased or absent FDG uptake (SUV ratio of 0.13-0.58, Type C, n = 6). In histologic examination, viable HCC tissue remained in all Type A and B tumors, whereas more than 90% necrosis was found in the Type C tumors, indicating that interventional therapy had been effective. These PET findings reflected tumor viability more accurately than the extent of intratumor Lipiodol retention on CT images.
CONCLUSION: FDG-PET appears to be a valuable method for the assessment of tumor viability after interventional therapy for HCC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989978

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

Review 1.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 2.  18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.

Authors:  B B Chin; R L Wahl
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 3.  What is the current situation in liver imaging?

Authors:  M M Uggowitzer
Journal:  Eur Radiol       Date:  2003-11       Impact factor: 5.315

4.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

5.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 6.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

7.  Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma.

Authors:  Sung Hoon Kim; Kyoung Sook Won; Byung Wook Choi; Il Jo; Seok Kil Zeon; Woo Jin Chung; Jung Hyeok Kwon
Journal:  Nucl Med Mol Imaging       Date:  2012-04-28

8.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.

Authors:  Tatsuya Higashi; Etsuro Hatano; Iwao Ikai; Ryuichi Nishii; Yuji Nakamoto; Koichi Ishizu; Tsuyoshi Suga; Hidekazu Kawashima; Kaori Togashi; Satoru Seo; Koji Kitamura; Yasutsugu Takada; Yasuji Takada; Shinji Uemoto; Shinji Kamimoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

10.  Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.

Authors:  B Böhm; M Voth; J Geoghegan; H Hellfritzsch; A Petrovich; J Scheele; D Gottschild
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.